Spanish consensus on premature menopause. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Mendoza, Nicolás; Juliá, Mª Dolores; Galliano, Daniela; Coronado, Pluvio; Díaz, Begoña; Fontes, Juan; Gallo, José Luis; García, Ana; Guinot, Misericordia; Munnamy, Merixtell; Roca, Beatriz; Sosa, Manuel; Tomás, Jordi; Llaneza, Plácido; Sánchez-Borrego, Rafael
• Is Part Of: Maturitas. Volume 80:Issue 2(2015:Feb.)
• Page Start: 220
• Page End: 225
• Publication Date: 2015-02
• Subjects: Primary ovarian insufficiency -- Premature menopause -- Hormonal therapy -- Fertility preservation -- Fertility treatments -- Osteoporosis; Climacteric -- Periodicals; Menopause -- Periodicals; Climacteric -- Periodicals; Geriatrics -- Periodicals; Menopause -- Periodicals; Middle Aged -- Periodicals; Climatère -- Périodiques; Ménopause -- Périodiques; Climacterium; Climacteric; Menopause; Electronic journals; Periodicals; 612.66
• DOI: 10.1016/j.maturitas.2014.11.007
• Languages: English
• ISSNs: 0378-5122

Abstract

Abstract: Introduction: While we recognise that the term premature menopause is more accepted by most non-specialist health care providers and by the general population, 'primary ovarian insufficiency' (POI) is currently considered the most apposite term to explain the loss of ovarian function, because it better explains the variability of the clinical picture, does not specify definitive failure, and highlights the specific ovarian source. Its pathogenesis involves a congenital reduction in the number of primordial follicles, poor follicle recruitment, or accelerated follicular apoptosis. However, its cause is unknown in most cases. Aim: This guide analyses the factors associated with the diagnosis and treatment of POI and provides recommendations on the most appropriate diagnostic and therapeutic measures for women under 40 years of age who experience POI. Methodology: A panel of experts from various Spanish scientific societies related to POI (Spanish Menopause Society, Spanish Fertility Society, and Spanish Contraception Society) met to reach a consensus on these issues. Results: Hormonal therapy (HT) is considered the treatment of choice to alleviate the symptoms of hypoestrogenism and to prevent long-term consequences. We suggest that HT should be continued until at least age 51, the average age at natural menopause. The best treatment to achieve pregnancy is oocyte/embryo donation. If a patient is to undergo treatment that will reduce her fertility, she should be informed of this issue and the available techniques to preserve ovarian function, mainly vitrification of oocytes.